Ketek 24,000-Patient Trial Should Be New “Benchmark” For Antibiotics
Executive Summary
Aventis' 24,000-patient "usual care" study for Ketek should be the benchmark for investigational antibiotic safety trials, FDA Anti-Infective Drugs Advisory Committee voting consultant William Lee, MD, University of Texas Southwestern Medical School, said Jan. 8
You may also be interested in...
Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin
Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal
Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin
Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal
Legislation On CROs And IRBs Might Be One Fall-Out From Ketek Probe
The House Energy and Commerce Committee is considering the need for legislation to set new parameters for organizations involved in drug development. Their concern is prompted by the failure of individuals overseeing safety study 3014 for Sanofi-Aventis' Ketek (telithromycin) to report investigator misconduct to FDA